April 26, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...




Inform patients that:

  • ConZip™ is for oral use only and should be swallowed whole. The capsule should not be chewed, dissolved, crushed or split.
  • ConZip™ may cause seizures and/or serotonin syndrome with concomitant use of serotonergic agents (including SRIs, NRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol.
  • Not to change the prescribed single-dose or 24-hour dosing regimen of ConZip™, and that exceeding the prescribed dose can result in respiratory depression, seizures or death.
  • ConZip™ may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  • ConZip™ should not be taken with alcohol containing beverages.
  • ConZip™ should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.
  • Instruct female patients to inform the prescriber if they are pregnant, think they might become pregnant, or are trying to become pregnant.
  • ConZip™ is to be taken once-a-day and at approximately the same time every day. Also, exceeding these recommendations and the maximum recommended daily dose can result in respiratory depression, seizures or death.
  • Elderly patients, especially those over 75 years of age, and other patients who have renal or hepatic impairments may need to be cautioned about reduced dosages.
  • Not to abruptly withdraw or discontinue tramadol therapy, as clinical experience with tramadol suggests the possible onset of signs and symptoms of withdrawal. These affects may be reduced by tapering tramadol therapy.
  • ConZip™ must be kept out of reach of children.

Last reviewed on RxList: 12/15/2016
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Chronic Pain/Back Pain

Find tips and advances in treatment.